The Influence of a Bupivacaine Digital Nerve Block Using Rev G.

University of California San Francisco (UCSF)

Status: Completed

Conditions: Patients Undergoing Spine Surgery

Treatments: Other: intermediate-acting digital nerve block

Study type: Interventional

Funder types: Other

Identifiers

NCT01750554

10-00524D

Details and patient eligibility

About

The investigators are proposing to continue investigation to improve the accuracy of the SpHb (continuous hemoglobin monitoring device) by administering an intermediate acting digital nerve block in the finger connected to the SpHb, specifically bupivacaine 0.25% in patients undergoing spine surgery. Bupivacaine is FDA approved and in routine use.

Full description

Patients undergoing spine surgery will be randomized to receive (or not) the bupivacaine digital block on the finger attached to the new limited release version of the hemoglobin sensor, RevG. The SpHb reading will be compared to a blood hemoglobin level analyzed in the UCSF Clinical Laboratories.

Enrollment: 19 patients

Sex: All

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female 18 years of age or older
• American Society of Anesthesiologists classification 1, 2 or 3
• Scheduled to undergo spine or hip surgery

Exclusion criteria

• Pregnant or nursing
• Patients who in the study investigators clinical judgement would not be suitable

Trial design

Primary purpose: Diagnostic

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

19 participants in 2 patient groups

bupivacaine digital nerve block

Experimental group

Description:

Patients undergoing spine surgery will have a 50/50 chance of being randomized to receive a bupivacaine 0.25% (2 milliliters total) intermediate-acting digital nerve block.

Treatment:

Other: intermediate-acting digital nerve block

No bupivacaine digital nerve block

No Intervention group

Description:

Patients undergoing spine surgery will have a 50/50 chance of being randomized to not receive a bupivacaine 0.25% (2 milliliters total) intermediate-acting digital nerve block.